Carola Maria Bregenzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carola Maria Bregenzer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Axel Rominger
Department of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
3 shared publications - Robert Seifert
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications - Clemens Mingels
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2 shared publications Jazan Omari
Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg and
2 shared publications- Konstantinos G. Zeimpekis
Department of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
2 shared publications Maciej Pech
Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg and
2 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (8) , 652-653
Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult Metastases
An 80-year-old man with hypercalcemia and hyperparathyroidism was suspected of having a parathyroid adenoma, which was localized on [ 18 F]F-choline-PET/CT. Still, after surgical removal of the suspected adenoma with an intraoperative parathyroid hormone decrease of >50%, severe hypercalcemia recurred quickly. A repeated [ 18 F]F-choline-PET/CT raised suspicion of a single contralateral parathyroid adenoma or multiglandular disease. Given the inconclusive findings, a histological reassessment of the suspected parathyroid adenoma showed the presence of a singular vessel invasion, which alerted the diagnosis to parathyroid carcinoma. An additionally performed [ 18 F]FDG-PET/CT revealed a liver lesion and MRI confirmed multiple liver metastases, which could not be seen on [ 18 F]F-choline-PET/CT.
- 17 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (8) , 652-653
Open AccessParathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult Metastases
An 80-year-old man with hypercalcemia and hyperparathyroidism was suspected of having a parathyroid adenoma, which was localized on [ 18 F]F-choline-PET/CT. Still, after surgical removal of the suspected adenoma with an intraoperative parathyroid hormone decrease of >50%, severe hypercalcemia recurred quickly. A repeated [ 18 F]F-choline-PET/CT raised suspicion of a single contralateral parathyroid adenoma or multiglandular disease. Given the inconclusive findings, a histological reassessment of the suspected parathyroid adenoma showed the presence of a singular vessel invasion, which alerted the diagnosis to parathyroid carcinoma. An additionally performed [ 18 F]FDG-PET/CT revealed a liver lesion and MRI confirmed multiple liver metastases, which could not be seen on [ 18 F]F-choline-PET/CT.
- Open Access
- 12 June 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Impact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation
This study compared quantitative accuracy and image quality of post-radioembolization selective internal radiation therapy (SIRT) 90Y PET/CT using a long a
- 12 June 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessImpact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation
This study compared quantitative accuracy and image quality of post-radioembolization selective internal radiation therapy (SIRT) 90Y PET/CT using a long a
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 300-308
Imaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice
Purpose: Guidelines recommend [ 18 F]FDG PET/CT for lung nodules >8 mm only. For smaller lesions, PET/CT has not been recommended due to lower lesion conspicuity. However, this threshold was established using earlier generations of PET scanners. In this work, we sought to evaluate the combined effects of modern scanner technology, long-axial-field-of-view (LAFOV) PET and data-driven respiratory motion correction on lung nodule imaging. Materials and Methods: We identified 55 consecutive patients with lung nodules who underwent [ 18 F]FDG PET/CT for a known or suspected malignancy. We created image reconstructions with combinations of simulated short-axial-field-of-view (sSAFOV), LAFOV, and data-driven gating (DDG) and measured effects on image parameters. We then gathered follow-up data (over 13 mo) to establish nodule benignity or malignancy and evaluated effects on diagnostic accuracy with receiver-operating-characteristic (ROC) analysis. Results: All methods showed good to excellent diagnostic accuracy, even for nodules max by 32%. The combination of LAFOV and DDG showed the highest image quality improvement compared with sSAFOV, with a median improvement in contrast-to-noise ratio (CNR) of 29%. Conclusions: Data-driven motion correction and LAFOV-PET provide synergistic improvements in image quality. Furthermore, the high diagnostic accuracy of sSAFOV reconstructions for lung nodules ≤8 mm, and even <6 mm, indicates that assessment of lung nodules smaller than current guideline recommendations might be possible.
- 26 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 300-308
Open AccessImaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice
Purpose: Guidelines recommend [ 18 F]FDG PET/CT for lung nodules >8 mm only. For smaller lesions, PET/CT has not been recommended due to lower lesion conspicuity. However, this threshold was established using earlier generations of PET scanners. In this work, we sought to evaluate the combined effects of modern scanner technology, long-axial-field-of-view (LAFOV) PET and data-driven respiratory motion correction on lung nodule imaging. Materials and Methods: We identified 55 consecutive patients with lung nodules who underwent [ 18 F]FDG PET/CT for a known or suspected malignancy. We created image reconstructions with combinations of simulated short-axial-field-of-view (sSAFOV), LAFOV, and data-driven gating (DDG) and measured effects on image parameters. We then gathered follow-up data (over 13 mo) to establish nodule benignity or malignancy and evaluated effects on diagnostic accuracy with receiver-operating-characteristic (ROC) analysis. Results: All methods showed good to excellent diagnostic accuracy, even for nodules max by 32%. The combination of LAFOV and DDG showed the highest image quality improvement compared with sSAFOV, with a median improvement in contrast-to-noise ratio (CNR) of 29%. Conclusions: Data-driven motion correction and LAFOV-PET provide synergistic improvements in image quality. Furthermore, the high diagnostic accuracy of sSAFOV reconstructions for lung nodules ≤8 mm, and even <6 mm, indicates that assessment of lung nodules smaller than current guideline recommendations might be possible.
- Open Access
- 1 December 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1)
Automation of 99mTc mercaptoacetyltriglycine (MAG3) report writing using a vision language model
99mTc mercaptoacetyltriglycine (MAG3) studies represent a classic of nuclear medicine. We evaluated the quality of MAG3 reports generated by a vision langu
- 1 December 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1)
Open AccessAutomation of 99mTc mercaptoacetyltriglycine (MAG3) report writing using a vision language model
99mTc mercaptoacetyltriglycine (MAG3) studies represent a classic of nuclear medicine. We evaluated the quality of MAG3 reports generated by a vision langu
- 30 October 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (1) , 34-40
Y90 radioembolization in advanced liver cancer of rarely treated tumor entities: prediction of treatment response and survival by clinical and imaging features
Background: Radioembolization is classically used in patients with hepatocellular carcinoma and secondary hepatic malignancies like colorectal cancer and neuroendocrine tumors. Up to now, data for other hepatic metastasized tumor entities are rare, and it is not clear which clinical and imaging features could predict the outcome. Methods: Data of 60 patients exceptionally treated with radioembolization through the decision of an interdisciplinary board with tumor entities usually not treated by radioembolization were retrospectively analyzed. Hepatic features on cross-sectional preprocedural imaging, for example, like hypervascularization, hepatic tumor burden, maximum diameter, and clinical data, were also analyzed during follow-up. Predictive factors were calculated. Results: Univariate Cox regression showed a significant impact of different features on overall survival, for example, primary malignancy histology in the case of sarcoma, with 25 months median vs. 6 months median overall survival ( P = 0.015). Multivariate Cox regression revealed the two key factors for overall survival: arterial hypervascularization more than rim enhancement (15 vs. 6 months, P = 0.011, hazard ratio: 0.339) and hepatic tumor burden below 10% (18 vs. 5 months, P < 0.001, hazard ratio: 1.04). Conclusion: Preprocedural hypervascularization of liver malignancies and hepatic tumor burden are overall survival predicting factors in tumor entities rarely treated by radioembolization. Consideration of these factors can help to carry out suitable patient selection in the interdisciplinary board for radioembolization.
- 30 October 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 47 (1) , 34-40
Y90 radioembolization in advanced liver cancer of rarely treated tumor entities: prediction of treatment response and survival by clinical and imaging features
Background: Radioembolization is classically used in patients with hepatocellular carcinoma and secondary hepatic malignancies like colorectal cancer and neuroendocrine tumors. Up to now, data for other hepatic metastasized tumor entities are rare, and it is not clear which clinical and imaging features could predict the outcome. Methods: Data of 60 patients exceptionally treated with radioembolization through the decision of an interdisciplinary board with tumor entities usually not treated by radioembolization were retrospectively analyzed. Hepatic features on cross-sectional preprocedural imaging, for example, like hypervascularization, hepatic tumor burden, maximum diameter, and clinical data, were also analyzed during follow-up. Predictive factors were calculated. Results: Univariate Cox regression showed a significant impact of different features on overall survival, for example, primary malignancy histology in the case of sarcoma, with 25 months median vs. 6 months median overall survival ( P = 0.015). Multivariate Cox regression revealed the two key factors for overall survival: arterial hypervascularization more than rim enhancement (15 vs. 6 months, P = 0.011, hazard ratio: 0.339) and hepatic tumor burden below 10% (18 vs. 5 months, P < 0.001, hazard ratio: 1.04). Conclusion: Preprocedural hypervascularization of liver malignancies and hepatic tumor burden are overall survival predicting factors in tumor entities rarely treated by radioembolization. Consideration of these factors can help to carry out suitable patient selection in the interdisciplinary board for radioembolization.
- 31 July 2023
- Published by SAGE Publications in Acta Radiologica
- Vol. 64 (10) , 2783-2790
Cholecystitis induced by Yttrium-90 radioembolization of advanced liver tumors: prospective evaluation of a management algorithm in 197 consecutive patients
Background: Cholecystitis is a rare but dolorous complication after Y90-radioembolization of liver malignancies. Purpose: To decide the occlusion of the cystic artery (CA) to prevent cholecystitis after Y90 radioembolization using an algorithm. Material and Methods: In 130 patients, the gallbladder was at risk of embolization as the right liver lobe was targeted. Precautionary measures (e.g. coil occlusion of the cystic artery) were decided by enhancement of the gallbladder in pre-treatment Tc99m-MAA SPECT/CT and performed directly before Y90 radioembolization. In non-enhancing cases, the CA was left open. The outcome was determined by clinical symptoms of acute or chronic cholecystitis as well as imaging and laboratory parameters. Findings were additionally classified according to the Tokyo Guidelines of acute cholecystitis. Results: Only 16 patients demonstrated enhancement of the gallbladder in Tc99m-MAA SPECT/CT. Including additional indications from angiographic findings, prophylactic measures were scheduled in 22 patients (standard of care). Thus, 121 patients were at risk of non-target embolization to the gallbladder during Y90 microsphere administration (investigative arm). Four cases (3.0%) of cholecystitis occurred by clinical presentation: two patients with onset of acute symptoms within 48 h after Y90 radioembolization (“embolic cholecystitis”) and two patients with late onset of symptoms (“radiogenic cholecystitis”). The incidence of cholecystitis was not significantly more frequent without indication of precautionary measures (investigative cohort 2.9% vs. standard of care 4.7%; P = 0.53). Conclusion: The overall incidence of cholecystitis after Y90 radioembolization is low. Determination of cystic artery intervention using Tc99m-MAA SPECT/CT successfully balances the incidence of symptomatic cholecystitis with unnecessary vessel occlusion.
- 31 July 2023
- Published by SAGE Publications in Acta Radiologica
- Vol. 64 (10) , 2783-2790
Cholecystitis induced by Yttrium-90 radioembolization of advanced liver tumors: prospective evaluation of a management algorithm in 197 consecutive patients
Background: Cholecystitis is a rare but dolorous complication after Y90-radioembolization of liver malignancies. Purpose: To decide the occlusion of the cystic artery (CA) to prevent cholecystitis after Y90 radioembolization using an algorithm. Material and Methods: In 130 patients, the gallbladder was at risk of embolization as the right liver lobe was targeted. Precautionary measures (e.g. coil occlusion of the cystic artery) were decided by enhancement of the gallbladder in pre-treatment Tc99m-MAA SPECT/CT and performed directly before Y90 radioembolization. In non-enhancing cases, the CA was left open. The outcome was determined by clinical symptoms of acute or chronic cholecystitis as well as imaging and laboratory parameters. Findings were additionally classified according to the Tokyo Guidelines of acute cholecystitis. Results: Only 16 patients demonstrated enhancement of the gallbladder in Tc99m-MAA SPECT/CT. Including additional indications from angiographic findings, prophylactic measures were scheduled in 22 patients (standard of care). Thus, 121 patients were at risk of non-target embolization to the gallbladder during Y90 microsphere administration (investigative arm). Four cases (3.0%) of cholecystitis occurred by clinical presentation: two patients with onset of acute symptoms within 48 h after Y90 radioembolization (“embolic cholecystitis”) and two patients with late onset of symptoms (“radiogenic cholecystitis”). The incidence of cholecystitis was not significantly more frequent without indication of precautionary measures (investigative cohort 2.9% vs. standard of care 4.7%; P = 0.53). Conclusion: The overall incidence of cholecystitis after Y90 radioembolization is low. Determination of cystic artery intervention using Tc99m-MAA SPECT/CT successfully balances the incidence of symptomatic cholecystitis with unnecessary vessel occlusion.